Thierry Conrozier1, Jordi Monfort2, Xavier Chevalier3, Raghu Raman4, Pascal Richette5, Demirhan Diraçoglù6, Hervé Bard7, Dominique Baron8, Jörg Jerosch9, Alberto Migliore10, Yves Henrotin11. 1. Department of Rheumatology, Hôpital Nord Franche-Comté, Belfort, France. 2. Servei de Reumatologia, Hospital del Mar, Barcelona, Spain. 3. Paris XII University, UPEC, Department of Rheumatology, Henri Mondor Hospital, Creteil, France. 4. Academic Department of Orthopaedics, Hull and East Yorkshire NHS Trust Castle Hill Hospital, Cottingham, UK. 5. Université Paris Diderot, UFR Médicale, Hôpital Lariboisière, Paris, France. 6. Department of Physical Medicine and Rehabilitation, Istanbul University and Istanbul Faculty of Medicine, Istanbul, Turkey. 7. Department of Orthopaedics-Rheumatology, American Hospital of Paris, Neuilly/Seine, France. 8. Centre de réadaptation fonctionnelle de Lannion-Trestel, Trévou-Tréguignec, France. 9. Orthopedic Department, Johanna-Etienne-Hospital, Neuss, Nordrhein-Westfalen, Germany. 10. U.O.S. of Rheumatology, Ospedale San Pietro Fatebenefratelli, Rome, Italy. 11. Bone and Cartilage Research Unit, Université de Liège, CHU Sart-Tilman, Liège, Belgium.
Abstract
OBJECTIVES: The 3 aims of the work were to identify population subgroups that can benefit the most from viscosupplementation (VS), to provide recommendations on injection techniques, and to discuss VS appropriateness in clinical situations that are commonplace in daily practice. METHODS: The task force members voted on their degree of agreement on 27 statements, 36 recommendations, and 22 clinical scenarios using a 9-point scale. The strength of agreement/appropriateness/recommendation (SOA/SOR) was classified as strong if the median agreement score was ≥8. The level of consensus (LOC) was also obtained. RESULTS: Among the assumed predictors for VS failure, obesity, radiographic severity, large synovial fluid effusion, severe patellofemoral involvement, major malalignment, and gross joint instability received a large majority of agreements. The lateral mid-patellar approach was recommended for knee injection. Imaging guidance was unanimously recommended for hip and ankle. Agreement was achieved to strictly respect the dosing regimen proven by controlled trials. There was agreement for treating with VS patients with mild to moderate knee and hip OA, with normal weight or moderate overweight, insufficiently improved by first-line therapies, or who do not wish get oral treatment or who have contraindications to pain killers. The group considered the patient's wishes as a key element in therapeutic decision making. CONCLUSION: Based on literature data and clinical experience, the EUROVISCO group proposed a set of recommendations for optimizing the results of VS, aimed to help practitioners, especially in some cases in which the patients' specificities make the therapeutic decision difficult.
OBJECTIVES: The 3 aims of the work were to identify population subgroups that can benefit the most from viscosupplementation (VS), to provide recommendations on injection techniques, and to discuss VS appropriateness in clinical situations that are commonplace in daily practice. METHODS: The task force members voted on their degree of agreement on 27 statements, 36 recommendations, and 22 clinical scenarios using a 9-point scale. The strength of agreement/appropriateness/recommendation (SOA/SOR) was classified as strong if the median agreement score was ≥8. The level of consensus (LOC) was also obtained. RESULTS: Among the assumed predictors for VS failure, obesity, radiographic severity, large synovial fluid effusion, severe patellofemoral involvement, major malalignment, and gross joint instability received a large majority of agreements. The lateral mid-patellar approach was recommended for knee injection. Imaging guidance was unanimously recommended for hip and ankle. Agreement was achieved to strictly respect the dosing regimen proven by controlled trials. There was agreement for treating with VS patients with mild to moderate knee and hip OA, with normal weight or moderate overweight, insufficiently improved by first-line therapies, or who do not wish get oral treatment or who have contraindications to pain killers. The group considered the patient's wishes as a key element in therapeutic decision making. CONCLUSION: Based on literature data and clinical experience, the EUROVISCO group proposed a set of recommendations for optimizing the results of VS, aimed to help practitioners, especially in some cases in which the patients' specificities make the therapeutic decision difficult.
Authors: K M Jordan; N K Arden; M Doherty; B Bannwarth; J W J Bijlsma; P Dieppe; K Gunther; H Hauselmann; G Herrero-Beaumont; P Kaklamanis; S Lohmander; B Leeb; M Lequesne; B Mazieres; E Martin-Mola; K Pavelka; A Pendleton; L Punzi; U Serni; B Swoboda; G Verbruggen; I Zimmerman-Gorska; M Dougados Journal: Ann Rheum Dis Date: 2003-12 Impact factor: 19.103
Authors: Thomas H Trojian; Andrew L Concoff; Susan M Joy; John R Hatzenbuehler; Whitney J Saulsberry; Craig I Coleman Journal: Br J Sports Med Date: 2016-01 Impact factor: 13.800
Authors: Pascal Richette; Xavier Chevalier; Hang Korng Ea; Florent Eymard; Yves Henrotin; Paul Ornetti; Jérémie Sellam; Michel Cucherat; Marc Marty Journal: RMD Open Date: 2015-05-14
Authors: Gerard Malanga; Faizan Niazi; Vasco Deon Kidd; Edmund Lau; Steven M Kurtz; Kevin L Ong; Andrew L Concoff Journal: Am Health Drug Benefits Date: 2020-09
Authors: Carlos Gavín; Francisco J Blanco; José L Pablos; Miguel A Caracuel; José Rosas; Enrique Gómez-Barrena; Francisco Navarro; María Pilar Coronel; Mercedes Gimeno Journal: J Pain Res Date: 2021-07-21 Impact factor: 3.133